Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Ocugen ( (OCGN) ).
On September 11, 2025, Ocugen, Inc. entered into an Exclusive License Agreement with Kwangdong Pharmaceutical Co., Ltd., granting Kwangdong rights to commercialize OCU400 in South Korea. Ocugen will receive upfront and milestone payments, along with royalties, while Kwangdong will manage regulatory submissions and commercialization efforts in the region.
The most recent analyst rating on (OCGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Ocugen’s stock score is primarily impacted by its precarious financial position, characterized by persistent losses and high leverage. While technical indicators show strong bullish momentum, the negative P/E ratio and lack of dividend yield weigh heavily on valuation. The earnings call provided some optimism with progress in clinical trials and strategic partnerships, but concerns about cash reserves and expenses remain significant.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc. operates in the biotechnology industry, focusing on developing gene therapies for eye diseases. Its primary product, OCU400, is a novel modifier gene therapy aimed at treating retinitis pigmentosa.
Average Trading Volume: 4,175,142
Technical Sentiment Signal: Buy
Current Market Cap: $374.8M
Find detailed analytics on OCGN stock on TipRanks’ Stock Analysis page.